• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

The determination of recombinant human tissue-type plasminogen activator activity by turbidimetry using a microcentrifugal analyzer.

作者信息

Carlson R H, Garnick R L, Jones A J, Meunier A M

机构信息

Genentech, Inc., South San Francisco, California 94080.

出版信息

Anal Biochem. 1988 Feb 1;168(2):428-35. doi: 10.1016/0003-2697(88)90340-5.

DOI:10.1016/0003-2697(88)90340-5
PMID:3129963
Abstract

A method is described for determining the activity of recombinant human tissue-type plasminogen activator (rt-PA) by turbidimetry using a microcentrifugal analyzer (MCA). A mixture of thrombin and rt-PA is centrifuged into a mixture of fibrinogen and plasminogen to initiate clot formation and subsequent clot dissolution. The resultant profile of absorbance versus time is analyzed to determine the assay endpoint. Different rt-PA assay concentration ranges were studied in conjunction with profile endpoints for assay optimization. Spiked placebo recovery studies were used to evaluate assay accuracy and precision, which were determined to be 99.5 and 5% (relative standard deviation or RSD), respectively. Assay sensitivity was 0.5 ng/ml. Typical analysis time, including calculations, for a standard curve plus 14 samples was less than 30 min. The application of turbidimetry with the MCA for determining rt-PA activity provides rapid sample analysis and high throughput while maintaining accuracy and precision.

摘要

相似文献

1
The determination of recombinant human tissue-type plasminogen activator activity by turbidimetry using a microcentrifugal analyzer.
Anal Biochem. 1988 Feb 1;168(2):428-35. doi: 10.1016/0003-2697(88)90340-5.
2
Assessment of fibrinolytic activity by measuring the lysis time of a tissue-factor-induced clot: a feasibility evaluation.通过测量组织因子诱导的凝块的溶解时间来评估纤维蛋白溶解活性:可行性评估。
Clin Appl Thromb Hemost. 2010 Jun;16(3):337-44. doi: 10.1177/1076029608325542. Epub 2008 Dec 30.
3
A precise and rapid microtitre plate clot lysis assay: methodology, kinetic modeling and measurement of catalytic constants for plasminogen activation during fibrinolysis.一种精确快速的微量滴定板凝块溶解测定法:纤维蛋白溶解过程中纤溶酶原激活的方法、动力学建模及催化常数测定
Thromb Haemost. 1990 Nov 30;64(3):455-63.
4
Whole blood clot lysis in newborns and adults after adding different concentrations of recombinant tissue plasminogen activator (Rt-PA).添加不同浓度重组组织型纤溶酶原激活剂(Rt-PA)后新生儿和成人全血凝块的溶解情况。
Semin Thromb Hemost. 1998;24(6):599-604. doi: 10.1055/s-2007-996060.
5
In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.体外凝块溶解作为血栓对纤维蛋白溶解抵抗的潜在指标——在健康受试者中的研究及其与血液纤溶参数的相关性
Thromb Haemost. 1997 Apr;77(4):725-9.
6
Plasmin-mediated fibrinolysis by variant recombinant tissue plasminogen activators.变异重组组织型纤溶酶原激活剂介导的纤溶酶纤溶作用
Proc Natl Acad Sci U S A. 1989 Apr;86(8):2568-71. doi: 10.1073/pnas.86.8.2568.
7
The potency of tissue-type plasminogen activator (TPA) determined with chromogen and clot-lysis assays.采用发色底物法和凝块溶解法测定组织型纤溶酶原激活剂(TPA)的活性。
Biologicals. 1990 Apr;18(2):103-11. doi: 10.1016/1045-1056(90)90019-v.
8
Altered plasma fibrin clot properties in essential thrombocythemia.原发性血小板增多症患者的血浆纤维蛋白凝块特性改变。
Platelets. 2016;27(2):110-6. doi: 10.3109/09537104.2015.1042967. Epub 2015 May 19.
9
Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.荧光素标记的纤维蛋白原和纤维蛋白有助于在充分混合的条件下进行大分子组装以及对皮摩尔水平的纤溶酶原激活剂进行动态检测。
Thromb Haemost. 1995 Aug;74(2):711-7.
10
[Comparative randomized study of the effectiveness of intravenous recombinant tissue-type plasminogen activator and intravenous streptokinase in patients with acute myocardial infarct. Report of the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator].静脉注射重组组织型纤溶酶原激活剂与静脉注射链激酶治疗急性心肌梗死患者有效性的比较随机研究。欧洲重组组织型纤溶酶原激活剂合作研究组报告
Klin Wochenschr. 1988;66 Suppl 12:77-85.

引用本文的文献

1
Development and implementation of tPA clot lysis activity assay using ACL TOP™ hemeostasis testing system in QC laboratories.在质量控制实验室中使用ACL TOP™ 止血检测系统开发并实施组织型纤溶酶原激活剂(tPA)凝块溶解活性测定法。
Biotechnol Rep (Amst). 2017 Oct 27;16:58-64. doi: 10.1016/j.btre.2017.10.002. eCollection 2017 Dec.
2
Feasibility study on spray-drying protein pharmaceuticals: recombinant human growth hormone and tissue-type plasminogen activator.蛋白质药物喷雾干燥的可行性研究:重组人生长激素和组织型纤溶酶原激活剂
Pharm Res. 1994 Jan;11(1):12-20. doi: 10.1023/a:1018929224005.
3
Surface denaturation at solid-void interface--a possible pathway by which opalescent particulates form during the storage of lyophilized tissue-type plasminogen activator at high temperatures.
固-空界面处的表面变性——冻干组织型纤溶酶原激活剂在高温储存期间形成乳白色微粒的一种可能途径。
Pharm Res. 1995 Jan;12(1):69-77. doi: 10.1023/a:1016270103863.
4
Plasmin-mediated fibrinolysis by variant recombinant tissue plasminogen activators.变异重组组织型纤溶酶原激活剂介导的纤溶酶纤溶作用
Proc Natl Acad Sci U S A. 1989 Apr;86(8):2568-71. doi: 10.1073/pnas.86.8.2568.
5
Random PCR mutagenesis screening of secreted proteins by direct expression in mammalian cells.通过在哺乳动物细胞中直接表达对分泌蛋白进行随机PCR诱变筛选。
Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5467-71. doi: 10.1073/pnas.89.12.5467.